ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0088

Safety and Efficacy of the Anti-COVID-19 Vaccination Practiced During the Hemodialysis Session

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Lugli, Gianmarco, Universita degli Studi di Firenze, Firenze, Toscana, Italy
  • Spatoliatore, Giuseppe Lucian, Ospedale San Giovanni di Dio, Firenze, Toscana, Italy
  • Batazzi, Andrea, Universita degli Studi di Firenze, Firenze, Toscana, Italy
  • Pilo, Silvia, Universita degli Studi di Firenze, Firenze, Toscana, Italy
  • Rosati, Alberto, Ospedale San Giovanni di Dio, Firenze, Toscana, Italy
Background

CKD patients represent a population at high risk of mortality from Covid-19. For 3 years, our hospital has been running a complete intradyalitic vaccination project (HBV, Hemophylus, Pneumococcus, Influenza) for hemodialysis patients during dialysis treatment. This study aims to evaluate the safety and the serological response of intradialysis anti-Covid19 vaccination.

Methods

217 hemodialysis patients from 5 centers were vaccinated with Moderna (Fig. 1). Patients with a previous infection received only one dose. 10 patients (4.6%) refused the treatment. The administration took place one hour after the start of the dialysis session, and therefore with the session still in progress. 44 vaccinated patients, with no history of previous Covid19 infection, out of a total 80 dialysis patients, were selected on voluntary basis, in our HD-center, to measure and titrate the anti-RBD S1 antibodies of the virus spike antigen 14 days after the second dose.

Results

Of the 217 patients, 64.3% were male, with a mean age of 70 ± 14 years. 19 patients (8.7%) had mild adverse reactions at site of vaccine-inoculation. Neither serious adverse events nor intradialytic complications were recorded. Table 1 shows the characteristics of the 44 patients whose antibody titration was performed. Seroconversion was achieved in 41 patients (93.18%), anti-RBD S1 titer was 936,6 ± 661,7 UI/mL.

Conclusion

Our preliminary data form our study shows that intradialytic vaccination for Covid-19 is safe and effective and solves logistic problems in prophylaxis’s management. This approach should be preferred in hemodialysis patients. We are planning to extend anti-RBD S1 antibodies monitoring of the Sars-Cov2 virus in all HD Centers involved in the study and to include Peritoneal Dialysis' patients.

Figure 1